10/7/2009 2:31 AM EST
-
Diamyd Medical
Diamyd Medical announces today that 90 percent of the total 320 children and adolescents with type 1 diabetes due to participate in the company’s European Phase III study with the diabetes vaccine Diamyd® have now been included and have received injections of Diamyd® or placebo. The company expects all participants to have been included in the study by November 2009.
Diamyd Medical is conducting a global Phase...